Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
139 GBX | +1.83% | +1.09% | -23.84% |
May. 09 | Arecor Therapeutics collaborates with Medtronic on novel insulin | AN |
May. 09 | Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development | MT |
Sales 2023 * | 5.01M 6.28M | Sales 2024 * | 7.57M 9.49M | Capitalization | 41.81M 52.39M |
---|---|---|---|---|---|
Net income 2023 * | -6M -7.52M | Net income 2024 * | -6M -7.52M | EV / Sales 2023 * | 7.11 x |
Net cash position 2023 * | 6.16M 7.73M | Net cash position 2024 * | 2.07M 2.6M | EV / Sales 2024 * | 5.25 x |
P/E ratio 2023 * |
-5.69
x | P/E ratio 2024 * |
-6.35
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 day | +1.83% | ||
1 week | +1.09% | ||
Current month | +1.83% | ||
1 month | -0.71% | ||
3 months | -11.18% | ||
6 months | -23.84% | ||
Current year | -23.84% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | - |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 18-12-31 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 07-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | - |
Christine Soden
BRD | Director/Board Member | 66 | 21-04-30 |
Andrew Richards
CHM | Chairman | 64 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 139 | +1.83% | 7 519 |
24-05-09 | 136.5 | +1.11% | 14,069 |
24-05-08 | 135 | -1.82% | 6,494 |
24-05-07 | 137.5 | 0.00% | 35,011 |
24-05-03 | 137.5 | 0.00% | 17,518 |
Delayed Quote London S.E., May 10, 2024 at 03:21 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.84% | 52.32M | |
+23.37% | 47.02B | |
+49.79% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- AREC Stock